Robert W. Baird Trims Immutep (NASDAQ:IMMP) Target Price to $6.00

Immutep (NASDAQ:IMMP) had its price objective decreased by equities research analysts at Robert W. Baird from $7.00 to $6.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s target price suggests a potential upside of 116.61% from the company’s previous close.

Separately, Capital One Financial began coverage on Immutep in a report on Friday, May 17th. They issued an “overweight” rating and a $10.00 price objective for the company.

Immutep Trading Up 5.3 %

Shares of IMMP opened at $2.77 on Thursday. The business’s fifty day simple moving average is $2.75 and its two-hundred day simple moving average is $2.51. Immutep has a 12 month low of $1.58 and a 12 month high of $3.34.

Hedge Funds Weigh In On Immutep

A number of institutional investors and hedge funds have recently modified their holdings of IMMP. Meridian Wealth Management LLC increased its position in shares of Immutep by 3.6% during the 4th quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 11,250 shares during the last quarter. Virtu Financial LLC raised its position in Immutep by 269.4% in the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 32,864 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 4,700 shares during the last quarter. Oracle Investment Management Inc. grew its position in shares of Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after acquiring an additional 48,449 shares during the period. Finally, PFG Investments LLC purchased a new stake in shares of Immutep in the 1st quarter worth $119,000. 2.32% of the stock is currently owned by hedge funds and other institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.